Literature DB >> 32350952

Fulminant myocarditis and pulmonary cavity lesion induced by disseminated mucormycosis in a chronic hemodialysis patient: Report of an autopsied case.

Yuhei Fujisawa1, Satoshi Hara1, Takeshi Zoshima1, Naoto Maekawa2, Dai Inoue3, Motoko Sasaki4, Tadatsugu Gamou2, Yoji Nagata2, Kenshi Hayashi2, Akari Takeji1, Kiyoaki Ito1, Ichiro Mizushima1, Hiroshi Fujii1, Mitsuhiro Kawano1.   

Abstract

Mucormycosis is a rare fungal infection occurring in the immunocompromised host. It is difficult to diagnose, and its cardiac involvement is extremely rare. Here, we report a 64-year-old Japanese man with a 5-year history of hemodialysis with disseminated mucormycosis causing fulminant myocarditis and pulmonary necrosis under glucocorticoid use. Two months before, he had received an implantable cardioverter defibrillator and started to take amiodarone for recurrent ventricular arrhythmias due to hypertensive cardiomyopathy. He developed amiodarone-induced interstitial pneumonia and then received glucocorticoid therapy. Although the interstitial pneumonia partially improved, a lung cavitary lesion developed in the upper right lobe. Antibiotics had no effect, and serologic tests, blood and sputum cultures and bronchoalveolar lavage fluid were all negative for infectious pathogens. Eventually, he died of fulminant myocarditis. Autopsy revealed disseminated mucormycosis with vascular invasion and fungal thrombi, hemorrhage and infarction in lung (cavity lesion), heart (severe myocarditis), brain, thyroid and subcutaneous tissue around the implantable cardioverter defibrillator. The lung cavitary lesion was the only clinical finding suggestive of mucormycosis before autopsy. When an immunocompromised patient shows a progressive lung cavity lesion, the possibility of mucormycosis should be considered so that a broad-spectrum antifungal agent can be empirically administered in a timely fashion.
© 2020 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  disseminated mucormycosis; fulminant myocarditis; glucocorticoid; hemodialysis; pulmonary cavity lesion

Mesh:

Substances:

Year:  2020        PMID: 32350952     DOI: 10.1111/pin.12943

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  2 in total

1.  Disseminated Cunninghamella bertholletiae mucormycosis with protracted clinical course and formation of a large intra-ventricular mural thrombus.

Authors:  Masayuki Shintaku; Eiji Yamada; Makoto Ohta; Kohei Yoshikawa
Journal:  Int J Clin Exp Pathol       Date:  2022-05-15

Review 2.  Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients.

Authors:  P Monika; M N Chandraprabha
Journal:  Mol Biol Rep       Date:  2022-02-02       Impact factor: 2.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.